High Quality Levofloxacin Hydrochloride CAS No.: 177325-13-2 with Fast Delivery
Quick Details
CAS No.: 177325-13-2
Other Names: LEVOFLOXACIN HCL; carboxylic acid monohydrochloride; LevofloxacinHydro
MF: C18H21ClFN3O4
EINECS No.: C18H21ClFN3O4
Product Details
We take 'surpass ourselves and pursue excellence' as our foundation, continue to grow and develop, and create a legend in the Cas No. 84371-65-3, TEDA Triethylenediamine TEDA-A33, Dexamethasone Powder industry with quality and service. As always, we will adhere to the management policy of quality first and customer first, giving full play to our own advantages to establish our brand image. We develop and grow with the excellent effects and quality of our products. We will adhere to the policy of 'integrity, proactiveness, responsibility, and cooperation', and abide by the management philosophy of 'strict process quality, sound human management, and user first' to provide customers with the most satisfactory products and services.
Quick Details
CAS No.: 177325-13-2
Other Names: LEVOFLOXACIN HCL; carboxylic acid monohydrochloride; LevofloxacinHydro
MF: C18H21ClFN3O4
EINECS No.: C18H21ClFN3O4
Place of Origin: Jiangxi, China
Type: Antibiotic and Antimicrobial Agents
Grade Standard: Medicine Grade
Usage: Animal Pharmaceuticals
Brand Name: RQK Pharm
Model Number: BP USP26
Purity: 99%
color: Light yellow crystalline powder
standard: USP BP
character: pharmaceutical raw material
Packaging & Delivery
Packaging Details:25kg/drum
Delivery Time:within 7 working days after receiving L/C or deposit
We will provide you with customized solutions through professional services, in order to save money and expand revenue, we will provide you with the most appropriate design and High Quality Levofloxacin Hydrochloride CAS No.: 177325-13-2 with Fast Delivery with the lowest cost and the best service. Our company in line with to survive by quality and the spirit of winning customers with price. With the advent of the new economic era, the important role of innovation capabilities in the formation of corporate core competitive advantages will become more and more obvious.